Acknowledgement
- PDF / 123,769 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 54 Downloads / 164 Views
ACKNOWLEDGEMENT TO REFEREES
Ó Springer International Publishing Switzerland 2013 Dear Reader As we reach the final issue of CNS Drugs for 2013, we hope that you have found the articles published throughout the year to be interesting and informative. The editors and publishing staff have appreciated the high quality of content contributed to the journal this year. The publishing schedule for 2014 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year. The quality of articles published in CNS Drugs was acknowledged in the new Impact Factor for 2012, which increased over that for 2011 to reach a new high of 4.826. The journal is currently placed 24th in the Pharmacology and Pharmacy category, 20th in the Clinical Neurology category and 19th in the Psychiatry category. The Adis portfolio as a whole saw impressive Impact Factor gains, with flagship journals continuing to increase their citations – Drugs raised its Impact Factor to 4.633, with Clinical Pharmacokinetics and Sports Medicine also seeing significant rises to 6.109 and 5.237, respectively. Pharmacoeconomics remains the number one journal in its field, and The Patient: PatientCentered Outcomes Research saw an increase of more than 170 % in its Impact Factor to 1.565, only one year after first appearing in the Journal Citation ReportsÒ. 2013 saw the successful integration of the Adis portfolio of journals into the Springer production systems and custom-built platforms (SpringerLink, Springer for R&D, and Springer for Hospitals & Health). We are confident that our authors and subscribers benefit from improved discoverability, mobile optimisation and robust delivery of content on these platforms; and Springer production capacity has allowed us to increase the number of articles published whilst considerably reducing submission-to-publication times. Looking ahead to 2014, the Adis portfolio will continue to grow the amount of content published while maintaining high standards. The number of Adis titles will also increase as existing quality Springer journals are brought under the Adis brand - Advances in Therapy, Targeted Oncology, and the European Journal of Drug Metabolism and Pharmacokinetics. Adis are also committed to fostering Open Access publication: all Adis titles offer the Springer Open Choice option and we are adding a further 10 fully Open Access titles in specific therapy areas such as Diabetes Therapy, Cardiology and Therapy and Dermatology and Therapy, previously published under the Springer Healthcare imprint. Information about the portfolio can be found on Springer.com/Adis. We would like to thank all the authors who have contributed articles to CNS Drugs in the last 12 months. They have generously set aside time in their busy schedules to prepare content, and without their hard work and diligence we would not have been able to publish the journal. The quality of published articles also reflects the significant time and effort dedicated by the peer reviewers, who ensure that w
Data Loading...
